Working… Menu

Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00361322
Recruitment Status : Completed
First Posted : August 8, 2006
Last Update Posted : August 8, 2006
Information provided by:
Hadassah Medical Organization

Brief Summary:
The concept behind our study was to combine an effect of antibiotic and anti-inflammatory agents for a more efficient acne therapy directed at the factors involved in the pathophysiology of the disease. For this purpose we evaluated a combination of clindamycin phosphate and salicylic acid in a non-irritating carrier.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: clindamycin phosphate Drug: salicylic acid Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Topical Clindamycin Salicylic Acid Preparation for the Treatment of Acne Vulgaris
Study Start Date : April 2005
Study Completion Date : January 2006

Primary Outcome Measures :
  1. Lesions count at the baseline (week 0)
  2. Lesions count at the end of study (week 8)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • mild to moderate acne vulgaris;
  • at least 5 lesions on the face;
  • a one-month wash-out period was established for any topical or systemic drug use for treatment of acne vulgaris.

Exclusion Criteria:

  • acne that was primarily truncal, nodular, or due to secondary causes/internal disease;
  • pregnancy, breastfeeding, or intention to become pregnant;
  • another dermatological disease of the face;
  • significant systemic disease;
  • any drug/alcohol addiction;
  • interacting medication;
  • known hypersensitivity to study medications;
  • history of chronic disease treated with medications which might affect acne condition and treatment outcome (e.g. corticosteroids, lithium, isoniazid, anti-androgens, phenytoin, phenobarbital) in the preceding month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00361322

Layout table for location information
Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Vera Leibovici, MD Hadassah Medical Organization
Principal Investigator: Arie Ingber, MD, Prof Hadassah Medical Organization
Principal Investigator: Elka Touitou, PhD, Prof The Hebrew University of Jerusalem, Jerusalem, Israel

Layout table for additonal information Identifier: NCT00361322     History of Changes
Other Study ID Numbers: CLSA-HMO-CTIL
First Posted: August 8, 2006    Key Record Dates
Last Update Posted: August 8, 2006
Last Verified: August 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Clindamycin palmitate
Clindamycin phosphate
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Salicylic Acid
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antifungal Agents
Keratolytic Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors